Shinichi Hikasa1, Megumi Yasuda2, Kyoko Hideta3, Mai Kawakami3, Satoshi Higasa4, Akihiro Sawada4, Tazuko Tokugawa4, Takeshi Kimura3. 1. Department of Pharmacy, The Hospital of Hyogo College of Medicine, 1-1, Mukogawa-cho, Nishinomiya, Hyogo, 663-8501, Japan. ykhikasa@hyo-med.ac.jp. 2. Department of Pharmacy, School of Pharmacy, Hyogo University of Health Sciences, Kobe, Japan. 3. Department of Pharmacy, The Hospital of Hyogo College of Medicine, 1-1, Mukogawa-cho, Nishinomiya, Hyogo, 663-8501, Japan. 4. Division of Hematology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan.
Abstract
BACKGROUND: Renal dysfunction is recognized with increasing frequency among the noninfectious comorbidities associated with human immunodeficiency virus (HIV) infection. Urinary liver-type fatty acid-binding protein (L-FABP) has been shown to be a new biomarker to screen for not only tubulointerstitial damage but also kidney dysfunction. METHODS: We performed a cross-sectional study to determine the association between the urinary L-FABP and chronic kidney disease (CKD) among 77 HIV-infected Japanese patients by backward-stepwise multivariable logistic regression. RESULTS: The prevalence of individuals in the low risk was 80 %. Urinary L-FABP level was not associated with antiretroviral therapy and tenofovir disoproxil fumarate. On the other hand, urinary L-FABP level was independently associated with the CKD classification. CONCLUSION: Urinary L-FABP may be used as an adjunct to diagnose the CKD stage.
BACKGROUND:Renal dysfunction is recognized with increasing frequency among the noninfectious comorbidities associated with human immunodeficiency virus (HIV) infection. Urinary liver-type fatty acid-binding protein (L-FABP) has been shown to be a new biomarker to screen for not only tubulointerstitial damage but also kidney dysfunction. METHODS: We performed a cross-sectional study to determine the association between the urinary L-FABP and chronic kidney disease (CKD) among 77 HIV-infected Japanese patients by backward-stepwise multivariable logistic regression. RESULTS: The prevalence of individuals in the low risk was 80 %. Urinary L-FABP level was not associated with antiretroviral therapy and tenofovir disoproxil fumarate. On the other hand, urinary L-FABP level was independently associated with the CKD classification. CONCLUSION: Urinary L-FABP may be used as an adjunct to diagnose the CKD stage.
Authors: Ca Peralta; R Scherzer; C Grunfeld; A Abraham; Pc Tien; P Devarajan; M Bennett; Aw Butch; K Anastos; Mh Cohen; M Nowicki; A Sharma; Ma Young; Mj Sarnak; Cr Parikh; Mg Shlipak Journal: HIV Med Date: 2013-12-03 Impact factor: 3.180